Back to Search Results

Description

Details

Sub-Projects

Publications

Patents

Outcomes

Clinical Studies

News and More

History

Similar Projects

Prometheus: A Platform for Rapid Development of Human Antibody-based Therapeutics and Prophylactics against Emerging Viral Threats

Project Number
5U19AI142777-02

Contact PI/Project Leader
CHANDRAN, KARTIK

Awardee Organization
ALBERT EINSTEIN COLLEGE OF MEDICINE

Description

Abstract Text

The overarching goal of the Prometheus CETR is to discover and develop human antibody-based prophylactics and therapeutics against two major groups of Category A priority viruses that cause severe zoonotic disease—the nairovirus Crimean-Congo hemorrhagic fever virus (**CCHFV**), and the hantaviruses Andes virus (ANDV), Sin Nombre virus (SNV), and Puumula virus (PUUV). **CCHFV**, ANDV, and SNV are Category A agents that pose the highest risk to national security and public health. In their latest annual review, the World Health Organization designated CCHF as a Blueprint Priority Disease with the greatest potential to cause a public health emergency. There are no approved vaccines or treatments for any of these agents. The Prometheus CETR, an interwoven collaboration among seven partners from academia, government, and industry organized into two projects and three cores, will accomplish two Grand Goals that are each aimed at delivering a therapeutic product against our target viral pathogens. We will develop and deliver: (1) an antibody-based therapeutic with broad efficacy against **CCHFV**; and (2) an antibody-based therapeutic with broad efficacy against the hantaviruses ANDV and SNV.

Public Health Relevance Statement

No FDA-approved treatments exist for ebolaviruses, Crimean-Congo hemorrhagic fever virus (CCHFV), and the Andes and Sin Nombre hantaviruses, which are responsible for severe dis- ease in humans. The Prometheus CETR will develop and deliver treatments against each of these groups of viruses that are based on antibodies—natural immunity proteins speci?c for these viruses—isolated from humans who have recovered from infection. Such natural anti- body-based treatments can be more easily developed into drugs to treat people and with fewer risks of side effects.

Project Terms

Academia | Advanced Development | African | Americas | Andes Virus | Antibodies | Antibody Therapy | Blood specimen | Categories | Collaborations | Complement | Crimean-Congo Hemorrhagic Fever Virus | DNA | Data | Development | Disease | Disease Outbreaks | Ebola virus | Engineering | Epitopes | Etiology | Europe | Evaluation | FDA approved | Generations | Goals | Government | Half-Life | Hantavirus | Hantavirus Pulmonary Syndrome | Hemorrhagic Fever with Renal Syndrome | Human | Immunity | Individual | Industry | Infection | Injections | Lead | Mediating | Modeling | Monoclonal Antibodies | Nairovirus | National Security | Natural Immunity | Pharmaceutical Preparations | Production | Prophylactic treatment | Proteins

Read More

Details

Contact PI/ Project Leader

Name
CHANDRAN, KARTIK

Title
PROFESSOR

Contact
kchandra@aecom.yu.edu

Other PIs

Not Applicable

Program Official

Name
MARIC, MAJA

Contact
maricm@niaid.nih.gov

Organization

Name
ALBERT EINSTEIN COLLEGE OF MEDICINE

City
BRONX

Country
UNITED STATES (US)

Department Type
Unavailable

Organization Type
Domestic Higher Education

State Code
NY

Congressional District
14

Back to Search Results

Description

Details

Sub-Projects

Publications

Patents

Outcomes

Clinical Studies

News and More

History

Similar Projects

Prometheus: A Platform for Rapid Development of Human Antibody-based Therapeutics and Prophylactics against Emerging Viral Threats

Project Number
5U19AI142777-02

Contact PI/Project Leader
CHANDRAN, KARTIK

Awardee Organization
ALBERT EINSTEIN COLLEGE OF MEDICINE

2020 24-January-2020

Budget Start Date 01-February-2020

Budget End Date 31-January-2021

Project Funding Information for 2020

Total Funding
$4,452,397

Direct Costs
$3,690,697

Indirect Costs
$761,700

Year	Funding IC	FY Total Cost by IC
2020	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES	$4,452,397

Sub Projects

No Sub Projects information available for 5U19AI142777-02

Publications

No Publications available for 5U19AI142777-02

Patents

No Patents information available for 5U19AI142777-02

Outcomes

The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.

No Outcomes available for 5U19AI142777-02

Clinical Studies

No Clinical Studies information available for 5U19AI142777-02

News and More

Related News Releases

No news release information available for 5U19AI142777-02

History

No Historical information available for 5U19AI142777-02

Back to Search Results

Description

Details

Sub-Projects

Publications

Patents

Outcomes

Clinical Studies

News and More

History

Similar Projects

Prometheus: A Platform for Rapid Development of Human Antibody-based Therapeutics and Prophylactics against Emerging Viral Threats

Project Number
5U19AI142777-02

Contact PI/Project Leader
CHANDRAN, KARTIK

Awardee Organization
ALBERT EINSTEIN COLLEGE OF MEDICINE